Monopar Therapeutics (NASDAQ:MNPR) Director Sells $84,049.90 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 1,199 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $70.10, for a total transaction of $84,049.90. Following the transaction, the director owned 1,199 shares of the company’s stock, valued at approximately $84,049.90. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $71.42 on Friday. Monopar Therapeutics Inc. has a 12-month low of $50.07 and a 12-month high of $124.82. The stock’s 50 day moving average price is $86.88 and its two-hundred day moving average price is $77.39.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.02. Equities analysts predict that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Several large investors have recently made changes to their positions in MNPR. Bank of New York Mellon Corp bought a new position in Monopar Therapeutics during the 2nd quarter worth $7,124,000. Bank of America Corp DE lifted its holdings in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC raised its position in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Monopar Therapeutics in the 1st quarter worth about $250,000. Finally, Siren L.L.C. increased its stake in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MNPR. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Morgan Stanley restated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Finally, HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.00.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.